Keywords: Merck & Co, Financial results, Second-quarter 2012

Merck & Co hits four-year high, despite downturn in 2nd-qtr net income

Article | 30 July 2012

Print This

US pharma giant Merck & Co (NYSE: MRK) saw its shares rise 4.1% to $45.10 by Friday’s trading close, its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in